SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

American Renal Associates Holdings, Inc. – ‘10-Q’ for 3/31/17 – ‘R2’

On:  Tuesday, 5/9/17, at 4:50pm ET   ·   For:  3/31/17   ·   Accession #:  1498068-17-35   ·   File #:  1-37751

Previous ‘10-Q’:  ‘10-Q’ on 11/10/16 for 9/30/16   ·   Next:  ‘10-Q’ on 8/8/17 for 6/30/17   ·   Latest:  ‘10-Q’ on 11/6/20 for 9/30/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/09/17  American Renal Assocs Holdin… Inc 10-Q        3/31/17   73:5M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    520K 
 2: EX-10.1     Material Contract                                   HTML     43K 
 3: EX-10.2     Material Contract                                   HTML     40K 
 4: EX-10.3     Material Contract                                   HTML     39K 
 5: EX-10.4     Material Contract                                   HTML     41K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
16: R1          Document and Entity Information                     HTML     41K 
17: R2          Consolidated Balance Sheets                         HTML    115K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
19: R4          Consolidated Statements of Operations               HTML     81K 
20: R5          Consolidated Statements of Comprehensive (Loss)     HTML     35K 
                Income                                                           
21: R6          Consolidated Statement of Changes in Equity         HTML     78K 
22: R7          Consolidated Statements of Cash Flows               HTML    114K 
23: R8          Basis of Presentation and Organization              HTML     38K 
24: R9          Initial Public Offering                             HTML     41K 
25: R10         Cash                                                HTML     29K 
26: R11         Accounts Receivable                                 HTML     28K 
27: R12         Fair Value Measurements                             HTML     91K 
28: R13         Accrued Expenses and Other Current Liabilities      HTML     37K 
29: R14         Variable Interest Entities                          HTML     29K 
30: R15         Noncontrolling Interests Subject to Put Provisions  HTML     38K 
31: R16         Debt                                                HTML     52K 
32: R17         Income Taxes                                        HTML     27K 
33: R18         Stock-Based Compensation                            HTML     64K 
34: R19         (Loss) Earnings Per Share                           HTML     55K 
35: R20         Related Party Transactions                          HTML     35K 
36: R21         Commitments and Contingencies                       HTML     27K 
37: R22         Certain Legal Matters                               HTML     34K 
38: R23         Changes in Ownership Interest in Consolidated       HTML     38K 
                Subsidiaries                                                     
39: R24         Basis of Presentation and Organization (Policies)   HTML     40K 
40: R25         Cash (Tables)                                       HTML     34K 
41: R26         Fair Value Measurements (Tables)                    HTML     84K 
42: R27         Accrued Expenses and Other Current Liabilities      HTML     38K 
                (Tables)                                                         
43: R28         Debt (Tables)                                       HTML     47K 
44: R29         Stock-Based Compensation (Tables)                   HTML     64K 
45: R30         (Loss) Earnings Per Share (Tables)                  HTML     52K 
46: R31         Changes in Ownership Interest in Consolidated       HTML     35K 
                Subsidiaries (Tables)                                            
47: R32         Basis of Presentation and Organization (Details)    HTML     51K 
48: R33         Initial Public Offering (Details)                   HTML    107K 
49: R34         Cash (Details)                                      HTML     29K 
50: R35         Accounts Receivable (Details)                       HTML     30K 
51: R36         Fair Value Measurements (Details)                   HTML     30K 
52: R37         Fair Value Measurements - Schedule of fair values   HTML     58K 
                (Details)                                                        
53: R38         FAIR VALUE MEASUREMENTS - Fair value rollforward    HTML     30K 
                for tax receivable agreement liability (Details)                 
54: R39         Accrued Expenses and Other Current Liabilities      HTML     41K 
                (Details)                                                        
55: R40         Variable Interest Entities (Details)                HTML     24K 
56: R41         Noncontrolling Interests Subject to Put Provisions  HTML     25K 
                (Details)                                                        
57: R42         DEBT - Schedule of long-term debt (Details)         HTML     41K 
58: R43         DEBT - Scheduled maturities of long-term debt       HTML     40K 
                (Details)                                                        
59: R44         DEBT - Narrative (Details)                          HTML     51K 
60: R45         Income Taxes (Details)                              HTML     28K 
61: R46         STOCK-BASED COMPENSATION - Schedule of Expense      HTML     30K 
                (Details)                                                        
62: R47         STOCK-BASED COMPENSATION - Narrative (Details)      HTML     48K 
63: R48         STOCK-BASED COMPENSATION - Assumptions used for     HTML     33K 
                options granted (Details)                                        
64: R49         STOCK-BASED COMPENSATION - Option activity          HTML     54K 
                (Details)                                                        
65: R50         STOCK-BASED COMPENSATION - Restricted stock awards  HTML     40K 
                (Details)                                                        
66: R51         (Loss) Earnings Per Share (Details)                 HTML     56K 
67: R52         Related Party Transactions (Details)                HTML     58K 
68: R53         Commitments and Contingencies (Details)             HTML     22K 
69: R54         Certain Legal Matters (Details)                     HTML     28K 
70: R55         Changes in Ownership Interest in Consolidated       HTML     34K 
                Subsidiaries (Details)                                           
72: XML         IDEA XML File -- Filing Summary                      XML    121K 
71: EXCEL       IDEA Workbook of Financial Reports                  XLSX     67K 
10: EX-101.INS  XBRL Instance -- ara-20170331                        XML   1.02M 
12: EX-101.CAL  XBRL Calculations -- ara-20170331_cal                XML    194K 
13: EX-101.DEF  XBRL Definitions -- ara-20170331_def                 XML    428K 
14: EX-101.LAB  XBRL Labels -- ara-20170331_lab                      XML   1.34M 
15: EX-101.PRE  XBRL Presentations -- ara-20170331_pre               XML    757K 
11: EX-101.SCH  XBRL Schema -- ara-20170331                          XSD    126K 
73: ZIP         XBRL Zipped Folder -- 0001498068-17-000035-xbrl      Zip    165K 


‘R2’   —   Consolidated Balance Sheets


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Assets    
Cash $ 84,003 $ 100,916
Accounts receivable, less allowance for doubtful accounts of $9,227 and $8,726, respectively 77,495 81,127
Inventories 4,648 4,676
Prepaid expenses and other current assets 18,217 18,498
Income tax receivable 9,415 5,163
Total current assets 193,778 210,380
Property and equipment, net of accumulated depreciation of $129,540 and $121,242, respectively 167,338 170,118
Intangible assets, net of accumulated depreciation of $23,005 and $23,489, respectively 25,681 25,626
Other long-term assets 7,472 6,753
Goodwill 573,147 573,147
Total assets 967,416 986,024
Liabilities and Equity    
Accounts payable 24,605 31,127
Accrued compensation and benefits 26,092 29,103
Accrued expenses and other current liabilities 45,075 45,286
Current portion of long-term debt 45,559 48,274
Total current liabilities 141,331 153,790
Long-term debt, less current portion 520,364 522,058
Income tax receivable agreement payable 16,683 21,200
Other long-term liabilities 12,826 11,670
Deferred tax liabilities 1,522 1,278
Total Liabilities 692,726 709,996
Commitments and contingencies (Note 14 and Note 15)
Noncontrolling interests subject to put provisions 132,465 130,365
Equity:    
Preferred stock, $0.01 par value, 1,000,000 shares authorized; none issued
Common stock, $0.01 par value; 300,000,000 shares authorized; 31,143,998 and 30,894,962 issued and outstanding at March 31, 2017 and December 31, 2016, respectively 184 184
Additional paid-in capital 93,596 95,062
Receivable from noncontrolling interests (747) (544)
Accumulated deficit (129,897) (128,646)
Accumulated other comprehensive loss, net of tax (744) (100)
Total American Renal Associates Holdings, Inc. deficit (37,608) (34,044)
Noncontrolling interests not subject to put provisions 179,833 179,707
Total equity 142,225 145,663
Total liabilities and equity $ 967,416 $ 986,024

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/9/178-K
For Period end:3/31/17
12/31/1610-K
 List all Filings 
Top
Filing Submission 0001498068-17-000035   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 3:38:49.1pm ET